This puts Genentec as owner of tecentric(Atezolizumab) in competition with Merck for IMU in a trial sense.
Merck being involved in keytruda combo trial.
Two HUGE Pharmas heavily invested in reviewing our IMU drugs.
I know we are all waiting but this is great news for cancer sufferers and means all majors are interested in what LC and team have put together.
I am a believer so I think its just amazing that a small company in essentially 6 years (since first trial of Hervaxx) has created so much value.
I dont think they have wasted a dollar of shareholders funds.
Lets hope the share price reflects this value I perceive soon.
GLTA shareholder
This puts Genentec as owner of tecentric(Atezolizumab) in...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.4¢ |
Change
-0.003(3.45%) |
Mkt cap ! $614.8M | |||
| Open | High | Low | Value | Volume |
| 8.5¢ | 8.6¢ | 8.2¢ | $2.066M | 24.59M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 155713 | 8.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.4¢ | 140171 | 5 |
View Market Depth
| Last trade - 16.10pm 01/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.3¢ |
Change
-0.003 ( 4.16 %) |
||||
| Open | High | Low | Volume | ||
| 8.5¢ | 8.6¢ | 8.2¢ | 6789460 | ||
| Last updated 15.59pm 01/05/2024 ? | |||||
| IMU (ASX) Chart |